Ask AI
ProCE Banner Activity

ASC2ESCALATE: Asciminib in Patients With Chronic-Phase CML After 1 Prior TKI

Conference Coverage
Slideset

This report from the phase II ASC2ESCALATE trial evaluating asciminib in patients with CP-CML and 1 previous TKI not achieving optimal response milestones shows the trial met its primary endpoint of achieving MMR at 48 weeks with a manageable safety profile with asciminib as second-line therapy.

Released: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with malignant or nonmalignant hematologic disorders

  • Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders

  • Support informed shared decision-making for patients with malignant and nonmalignant hematologic disorders through accessible discussion of the potential clinical implications of recently presented data